title: High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
authors.forename: William
authors.initials: W
authors.lastname: Busse
authors.forename: Sheldon
authors.initials: S
authors.lastname: Spector
authors.forename: Karin
authors.initials: K
authors.lastname: Rosén
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Oral
authors.initials: O
authors.lastname: Alpan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D015415:Biomarkers / Q000032:analysis*; D002648:Child; D004802:Eosinophilia; D004804:Eosinophils; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D016896:Treatment Outcome; D014481:United States; D055815:Young Adult
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069444:Omalizumab